AI-based dose prediction for targeted radionuclide therapy in prostate cancer
Pre-therapeutic 68Ga-PSMA PET AI Based Dose Prediction for 177Lu-PSMA Targeted Radionuclide Therapy
Central Hospital, Nancy, France · NCT06268418
This study is testing if using artificial intelligence can help doctors figure out the best radiation doses for treating prostate cancer patients to better target tumors while reducing side effects.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 46 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | Male |
| Sponsor | Central Hospital, Nancy, France (other) |
| Drugs / interventions | radiation |
| Locations | 2 sites (Vandoeuvre les Nancy cedex and 1 other locations) |
| Trial ID | NCT06268418 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance targeted radionuclide therapy (TRT) for metastatic castration-resistant prostate cancer (mCRPC) by utilizing artificial intelligence to predict optimal radiation doses tailored to individual patients. It focuses on generating a 3D time integrated activity (TIA) map based on pre-therapy imaging and physiologically based pharmacokinetic (PBPK) modeling. The goal is to improve the balance between effective tumor destruction and minimizing side effects by providing personalized treatment planning. The study will involve patients who have received 177Lu-PSMA therapy and undergone 68Ga-PSMA PET/CT imaging.
Who should consider this trial
Good fit: Ideal candidates are patients who have received at least one dose of 177Lu-PSMA and have undergone a 68Ga-PSMA PET/CT scan as part of their pre-treatment assessment.
Not a fit: Patients who oppose the use of their data for research purposes will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and safer treatment plans for patients undergoing TRT for prostate cancer.
How similar studies have performed: While the use of AI in dose prediction is a growing field, this specific approach utilizing PBPK modeling and TIA mapping for TRT is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who received at least one dose of 177Lu-PSMA and for whom a 68Ga-PSMA PET/CT was performed as part of IVRT in the "pre-treatment" assessment Exclusion Criteria: * Patient opposition to the use of their data as part of this research.
Where this trial is running
Vandoeuvre les Nancy cedex and 1 other locations
- CHRU de NANCY — Vandoeuvre les Nancy cedex, France (COMPLETED)
- Nuclear medicine Department CHRU de NANCY — Vandoeuvre les Nancy cedex, France (RECRUITING)
Study contacts
- Study coordinator: VERONIQUE ROCH, MSc
- Email: v.roch@chru-nancy.fr
- Phone: 383154276
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Radionucleide Therapy